124 related articles for article (PubMed ID: 14758768)
1. JAK3 inhibition as a new concept for immune suppression.
Borie DC; Si MS; Morris RE; Reitz BA; Changelian PS
Curr Opin Investig Drugs; 2003 Nov; 4(11):1297-303. PubMed ID: 14758768
[TBL] [Abstract][Full Text] [Related]
2. A new modality for immunosuppression: targeting the JAK/STAT pathway.
O'Shea JJ; Pesu M; Borie DC; Changelian PS
Nat Rev Drug Discov; 2004 Jul; 3(7):555-64. PubMed ID: 15232577
[No Abstract] [Full Text] [Related]
3. Jak3, severe combined immunodeficiency, and a new class of immunosuppressive drugs.
Pesu M; Candotti F; Husa M; Hofmann SR; Notarangelo LD; O'Shea JJ
Immunol Rev; 2005 Feb; 203():127-42. PubMed ID: 15661026
[TBL] [Abstract][Full Text] [Related]
4. JAK3 inhibition, a viable new modality of immunosuppression for solid organ transplants.
Borie DC; O'Shea JJ; Changelian PS
Trends Mol Med; 2004 Nov; 10(11):532-41. PubMed ID: 15519279
[TBL] [Abstract][Full Text] [Related]
5. Janus kinase-3 (JAK3) inhibition: a novel immunosuppressive option for allogeneic transplantation.
Säemann MD; Zeyda M; Stulnig TM; Böhmig GA; Wekerle T; Hörl WH; Zlabinger GJ
Transpl Int; 2004 Oct; 17(9):481-9. PubMed ID: 15368094
[TBL] [Abstract][Full Text] [Related]
6. Jak3 and the pathogenesis of severe combined immunodeficiency.
O'Shea JJ; Husa M; Li D; Hofmann SR; Watford W; Roberts JL; Buckley RH; Changelian P; Candotti F
Mol Immunol; 2004 Jul; 41(6-7):727-37. PubMed ID: 15220007
[TBL] [Abstract][Full Text] [Related]
7. Targeting the Jak/STAT pathway for immunosuppression.
O'shea JJ
Ann Rheum Dis; 2004 Nov; 63 Suppl 2(Suppl 2):ii67-ii71. PubMed ID: 15479876
[No Abstract] [Full Text] [Related]
8. JAK protein kinase inhibitors.
Thompson JE
Drug News Perspect; 2005 Jun; 18(5):305-10. PubMed ID: 16193102
[TBL] [Abstract][Full Text] [Related]
9. Targeting Jak3 for immune suppression and allograft acceptance.
Kirken RA
Transplant Proc; 2001; 33(7-8):3268-70. PubMed ID: 11750399
[No Abstract] [Full Text] [Related]
10. Is JAK3 a new drug target for immunomodulation-based therapies?
Papageorgiou AC; Wikman LE
Trends Pharmacol Sci; 2004 Nov; 25(11):558-62. PubMed ID: 15491777
[TBL] [Abstract][Full Text] [Related]
11. Autosomal SCID caused by a point mutation in the N-terminus of Jak3: mapping of the Jak3-receptor interaction domain.
Cacalano NA; Migone TS; Bazan F; Hanson EP; Chen M; Candotti F; O'Shea JJ; Johnston JA
EMBO J; 1999 Mar; 18(6):1549-58. PubMed ID: 10075926
[TBL] [Abstract][Full Text] [Related]
12. CP-690550, a JAK3 inhibitor as an immunosuppressant for the treatment of rheumatoid arthritis, transplant rejection, psoriasis and other immune-mediated disorders.
West K
Curr Opin Investig Drugs; 2009 May; 10(5):491-504. PubMed ID: 19431082
[TBL] [Abstract][Full Text] [Related]
13. Suppression of early T-cell-receptor-triggered cellular activation by the Janus kinase 3 inhibitor WHI-P-154.
Säemann MD; Zeyda M; Diakos C; Szekeres A; Böhmig GA; Kelemen P; Parolini O; Stockinger H; Prieschl EE; Stulnig TM; Baumruker T; Zlabinger GJ
Transplantation; 2003 Jun; 75(11):1864-72. PubMed ID: 12811247
[TBL] [Abstract][Full Text] [Related]
14. Immunosuppression by the JAK3 inhibitor CP-690,550 delays rejection and significantly prolongs kidney allograft survival in nonhuman primates.
Borie DC; Changelian PS; Larson MJ; Si MS; Paniagua R; Higgins JP; Holm B; Campbell A; Lau M; Zhang S; Flores MG; Rousvoal G; Hawkins J; Ball DA; Kudlacz EM; Brissette WH; Elliott EA; Reitz BA; Morris RE
Transplantation; 2005 Apr; 79(7):791-801. PubMed ID: 15818321
[TBL] [Abstract][Full Text] [Related]
15. Prevention of organ allograft rejection by a specific Janus kinase 3 inhibitor.
Changelian PS; Flanagan ME; Ball DJ; Kent CR; Magnuson KS; Martin WH; Rizzuti BJ; Sawyer PS; Perry BD; Brissette WH; McCurdy SP; Kudlacz EM; Conklyn MJ; Elliott EA; Koslov ER; Fisher MB; Strelevitz TJ; Yoon K; Whipple DA; Sun J; Munchhof MJ; Doty JL; Casavant JM; Blumenkopf TA; Hines M; Brown MF; Lillie BM; Subramanyam C; Shang-Poa C; Milici AJ; Beckius GE; Moyer JD; Su C; Woodworth TG; Gaweco AS; Beals CR; Littman BH; Fisher DA; Smith JF; Zagouras P; Magna HA; Saltarelli MJ; Johnson KS; Nelms LF; Des Etages SG; Hayes LS; Kawabata TT; Finco-Kent D; Baker DL; Larson M; Si MS; Paniagua R; Higgins J; Holm B; Reitz B; Zhou YJ; Morris RE; O'Shea JJ; Borie DC
Science; 2003 Oct; 302(5646):875-8. PubMed ID: 14593182
[TBL] [Abstract][Full Text] [Related]
16. New strategies for immunosuppression: interfering with cytokines by targeting the Jak/Stat pathway.
O'Shea JJ; Park H; Pesu M; Borie D; Changelian P
Curr Opin Rheumatol; 2005 May; 17(3):305-11. PubMed ID: 15838241
[TBL] [Abstract][Full Text] [Related]
17. JAK3, STAT, and MAPK signaling pathways as novel molecular targets for the tyrphostin AG-490 regulation of IL-2-mediated T cell response.
Wang LH; Kirken RA; Erwin RA; Yu CR; Farrar WL
J Immunol; 1999 Apr; 162(7):3897-904. PubMed ID: 10201908
[TBL] [Abstract][Full Text] [Related]
18. Novel immunosuppression: R348, a JAK3- and Syk-inhibitor attenuates acute cardiac allograft rejection.
Deuse T; Velotta JB; Hoyt G; Govaert JA; Taylor V; Masuda E; Herlaar E; Park G; Carroll D; Pelletier MP; Robbins RC; Schrepfer S
Transplantation; 2008 Mar; 85(6):885-92. PubMed ID: 18360272
[TBL] [Abstract][Full Text] [Related]
19. Janus kinase 3: a novel target for selective transplant immunosupression.
Podder H; Kahan BD
Expert Opin Ther Targets; 2004 Dec; 8(6):613-29. PubMed ID: 15584866
[TBL] [Abstract][Full Text] [Related]
20. Mutations in severe combined immune deficiency (SCID) due to JAK3 deficiency.
Notarangelo LD; Mella P; Jones A; de Saint Basile G; Savoldi G; Cranston T; Vihinen M; Schumacher RF
Hum Mutat; 2001 Oct; 18(4):255-63. PubMed ID: 11668610
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
